Press release
Why the Non-Small Cell Lung Cancer Therapeutics Market is set to explode? Top Companies: Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene Corporation and more
Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/non-small-cell-lung-cancer-therapeutics-market-100484
Some of the key companies that are present in the Global Non-Small Cell Lung Cancer Therapeutics Market are;
• Genentech (F. Hoffmann-La Roche Ltd)
• Eli Lilly and Company
• Celgene Corporation
• AstraZeneca
• Pfizer Inc.
• Sanofi
• Novartis AG
• Astellas
• Bristol Myers Squibb
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Millennium Pharmaceuticals, Inc. (Takeda)
• Merck Sharp & Dohme Corp.
• Other players
The Global Non-Small Cell Lung Cancer Therapeutics Market is growing impressively due to recent surge in adoption of targeted therapy for treating non-small cell lung cancer. According to a report published by Fortune Business Insights, titled ‘Non-Small Cell Lung Cancer Therapeutics: Global Market Analysis, Insights and Forecasts, 2019-2026,’ the market value will rise substantially from US$ 16,011.7 Mn in 2018 to US$ 43,713.1 Mn by 2026.
Lung cancers account for majority of the cancer-related deaths, worldwide. Furthermore, non-small cell lung cancer account for more than 80% of the total cancer cases. Such high mortality rates have created an awareness among people, subsequently increasing demand for detection of lung cancer at an early stage. With growing demand for early disease detection, companies are increasingly investing towards developing efficient diagnosis methods and tools.
Get Sample PDF Brochure at
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/non-small-cell-lung-cancer-therapeutics-market-100484
Incorporation of Biological Therapies in Non-Small Cell Lung Cancer Therapeutics to Enable Growth
In recent years, the demand for efficient diagnosis method to treat non-small lung cancer is rising at a fast pace. Clinical studies indicated that biological therapies have massively reduced mortality rate of those affected with non-small cell lung cancer. The development of novel biological therapies has been hugely beneficial in treating non-small cell lung cancer (NSCLC). Biological therapies have had a positive impact on the molecular subsets of various lung cancer categories. NSCLC treatments have been blessed with various advancements in biological therapy concepts and they are now playing a major part in minimizing symptoms of non-small cell lung cancer as well. Thus, the use of biological therapies had a positive impact on the global NSCLC therapeutics market and is likely to favour growth of this market in the forecast period.
Segmentation
By Therapy
• Targeted Therapy
• Immunotherapy
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
By Cancer Type
• Adenocarcinoma
• Squamous cell carcinoma
• Large cell carcinoma
By Geography
Adenocarcinoma to Emerge as The Leading Segment
According to cancer.org, adenocarcinoma accounted for 40% of all lung cancers. Although prevalence of adenocarcinoma is high, it is the least deadly among all types of lung cancers. Adenocarcinoma allows for easy NSCLC prognosis as it can be detected at a very early stage. Furthermore, adenocarcinoma can be treated easily as they spread at a slower rate than other NSCLCs. High chances of diagnosis of adenocarcinoma is a major factor why adenocarcinoma will emerge as the leading segment in the forecast period, as well.
Some of the leading companies that are operating in the global non-small cell lung cancer therapeutics market are Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene Corporation, AstraZeneca, Pfizer Inc., Sanofi, Novartis AG, Astellas, Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc. (Takeda), Merck Sharp & Dohme Corp. and others.
Major Table of Content
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1 Prevalence of Non Small Cell Lung Cancer by Type
4.2 Regulatory Scenario by Key Regions
4.3 Key Industry Developments
4.4 Pipeline Analysis
4.5 Overview of Current Advances in R&D for Non Small Cell Lung Cancer Therapeutics
5. Global Non SmallCell Lung Cancer Therapeutics Market Analysis, Insights and Forecast, 2015-2026
TOC Continued….!
Get Discount at
https://www.fortunebusinessinsights.com/enquiry/check-discount/non-small-cell-lung-cancer-therapeutics-market-100484
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com
About Us:
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Why the Non-Small Cell Lung Cancer Therapeutics Market is set to explode? Top Companies: Genentech (F. Hoffmann-La Roche Ltd), Eli Lilly and Company, Celgene Corporation and more here
News-ID: 1848179 • Views: …
More Releases from Fortune Business Insights
Future of Renewable Energy Market Insights: Growth Drivers, and Regional Develop …
Global Renewable Energy Market Overview
The global renewable energy market size was valued at USD 954 billion in 2023. The market is projected to grow from USD 1,020.94 billion in 2024 to USD 1,574.17 billion by 2032, exhibiting a CAGR of 5.56% during the forecast period. Asia Pacific dominated the renewable energy market with a market share of 67.76% in 2023. The Renewable energy market in the U.S. is projected to…
DC Drives Market Overview: Opportunities, Growth Drivers, and Key Applications
Market Overview
The global DC drives market size was valued at USD 4.34 billion in 2018 and is projected to reach USD 9.23 billion by 2032, exhibiting a CAGR of 5.59% during the forecast period of 2019-2032. Asia Pacific dominated the global market with a share of 28.8% in 2018. The DC drives market in the U.S. is projected to grow significantly, reaching an estimated value of USD 1.59 billion by…
Humanoid Robots Market: An In-depth B2B Analysis of Size, Share, and Future Grow …
Brief Market Overview:
The global humanoid robots market is rapidly transitioning from a nascent field into a major growth sector, with its value escalating from USD 2.43 billion in 2023 to a projected USD 66.0 billion by 2032, demonstrating a remarkable CAGR of 45.5%.
These complex machines, which merge mechanical, electrical, and software engineering, are moving beyond research labs into real-world applications across industrial, service, and household sectors. This explosive growth…
Methanol Market Poised for Remarkable Growth, set to Reach USD 46.32 billion by …
The global methanol market size was valued at USD 31.26 billion in 2023. It is projected to grow from USD 32.70 billion in 2024 to USD 46.32 billion by 2032, exhibiting a CAGR of 4.5% during the forecast period.
The global methanol market size is set to gain traction from the urgent need to lower environmental pollution caused by the surging usage of heavy fuels, such as diesel and gasoline. Pollution…
More Releases for Lung
Lung Cancer Prevalence Driving The Lung Cancer Drugs Market: Core Growth Enabler …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Lung Cancer Drugs Industry Market Size Be by 2025?
The market for lung cancer medications has seen a swift expansion in previous years. The market size is projected to escalate from $47.94 billion in 2024 to $54.13 billion in 2025, with a compound annual growth rate…
Lung Cancer Prevalence Driving The Lung Cancer Drugs Market: An Emerging Driver …
The Lending And Payments Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Lending And Payments Market?
The lending and payments market has experienced strong growth in recent years. It is set to rise from $12,326.44 billion in 2024 to…
Transforming the Lung Cancer Drugs Market in 2025: Lung Cancer Prevalence Drivin …
What Is the Expected Size and Growth Rate of the Lung Cancer Drugs Market?
The market size for lung cancer medications has seen swift expansion in the recent past. Its growth is projected to surge from $47.94 billion in 2024 to $54.13 billion in 2025, marking a compound annual growth rate (CAGR) of 12.9%. Factors contributing to the historical period's growth include epidemiology and demographics, regulatory authorizations, healthcare system infrastructure, and…
Transforming the Lung Cancer Drugs Market in 2025: Lung Cancer Prevalence Drivin …
What Is the Expected Size and Growth Rate of the Lung Cancer Drugs Market?
The market size for lung cancer medications has seen swift expansion in the recent past. Its growth is projected to surge from $47.94 billion in 2024 to $54.13 billion in 2025, marking a compound annual growth rate (CAGR) of 12.9%. Factors contributing to the historical period's growth include epidemiology and demographics, regulatory authorizations, healthcare system infrastructure, and…
Lung Cancer Screening Market - Empowering Proactive Lung Health: The Future of C …
Newark, New Castle, USA: The "Lung Cancer Screening Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Lung Cancer Screening Market: https://www.growthplusreports.com/report/lung-cancer-screening-market/7787
This latest report researches the industry structure,…
Artificial Lung Market May Set New Growth Story | Breethe, Lung Biotechnology, M …
A new research document is added in HTF MI database of 37 pages, titled as 'Artificial Lung - Medical Devices Pipeline Assessment, 2020' with detailed analysis, Competitive landscape, forecast and strategies. The study covers important players/vendors such as ALung Technologies Inc, Breethe, Inc., Case Western Reserve University, Lung Biotechnology PBC, MC3 Inc, McGowan Institute for Regenerative , Medicine, Miromatrix Medical Inc, The Charles Stark Draper Laboratory Inc, U.S. Ann Arbor…
